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Abstract
Background: Nivolumab, an immune checkpoint inhibitor, is recently clinically applied to non-small cell lung
cancer (NSCLC) treatment, and this causes T cell activation and T cell infiltration to tumor tissue through the
blockade of the interaction between programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1).
18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) sometimes shows false positive because of the
recruitment of neutrophils, lymphocytes, and macrophages. To date, there is only one report except our case,
which described the correlation between FDG-PET and nivolumab.
Case presentation: We report on a 75-year-old man on nivolumab treatment for metastatic non-small cell lung
cancer. He had undergone right lower lobectomy for lung adenocarcinoma in the right S8 segment 10 months
prior to recurrence. Pathological findings revealed invasive adenocarcinoma, pT1bN2M0 stage IIIA. Epidermal
growth factor receptor (EGFR) mutation was positive for de novo T790M and anaplastic lymphoma kinase (ALK)
rearrangement was negative. Immunohistochemistry was negative for PD-L1. He underwent chemotherapy with a
combination of cisplatin and pemetrexed for four cycles but developed progressive disease involving the right
hemithorax, multiple lymph nodes, and multiple osseous sites. Nivolumab was instituted as a second-line
chemotherapy. After six courses of this immunotherapy, FDG-PET scan showed decreased FDG uptake in each
recurrent lesion despite T lymphocyte activation by nivolumab. Serum carcinoembryonic antigen (CEA) level was
also remarkably decreased.
Conclusions: Nivolumab’s effect on recurrent NSCLC may be monitored by PET; larger studies are needed.
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Background
Lung cancer is the leading cause of cancer-related death
worldwide [1]. Advances in the treatment of non-smallcell
lung cancer (NSCLC) in the past decade include third-
generation platinum doublets, epidermal growth factor re-
ceptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR
mutation-positive lung cancer, anaplastic lymphoma kin-
ase (ALK) TKIs in ALK rearrangement-positive disease,
maintenance systemic therapy, and second- or third-
line treatment, which improve survival [2–9]. In recent
years, immune checkpoint inhibitors have been intro-
duced [10–12], and their effectiveness is promising.
Nivolumab, an immune checkpoint inhibitor that is an
antibody against programmed death-1 (PD-1), causes T
cell activation and demonstrates clinically relevant anti-
tumor activity. In some phase III trials, overall survival
(OS), objective response rate (ORR), and progression-
free survival (PFS) were better with nivolumab than
with docetaxel in NSCLC [13, 14].
18F-fluorodeoxyglucose-positron emission tomography
(FDG-PET) is an effective tool for assessing treatment
response and surveillance of disease recurrence; however,
it sometimes shows increased FDG uptake at sites of local
inflammatory changes caused by the recruitment of neu-
trophils, lymphocytes, and macrophages [15]. We present
a case of a patient with metastatic NSCLC who underwent
nivolumab treatment as a second line chemotherapy and
whose PET scan showed decreased FDG uptake after
treatment in spite of nivolumab’s known T cell activation
properties.
Case presentation
A 75-year-old man was admitted to our hospital because
of metastatic NSCLC. He had undergone right lower
lobectomy for lung adenocarcinoma originating in the
right S8 segment as initial treatment. Postoperative find-
ings revealed invasive adenocarcinoma with pT1bN2M0
stage IIIA. An EGFR mutation was positive for de novo
T790M, and ALK rearrangement was negative.
Immunohistochemistry was negative for programmed
death ligand 1 (PD-L1) (Fig. 1). Ten months after his ini-
tial surgery, recurrence was detected in the form of mul-
tiple bone and lymph nodes metastases and right
intrathoracic dissemination. He underwent chemother-
apy with a combination of cisplatin and pemetrexed for
four cycles (Bevacizumab was withheld because of his
past history of cerebral hemorrhage.). After first line
chemotherapy, his clinical imaging revealed increasing
size and number of metastatic sites, which were graded
as progressive disease (PD) according to the Response
Evaluation Criteria in Solid Tumors 1.1 (RECIST) [16].
We decided to administer nivolumab (3 mg/kg) every
2 weeks as a second-line chemotherapy. Before starting
this immunotherapy, his medical check-up revealed
stable borderline diabetes. Hormonal examination such
as adrenocorticotropic hormone (ACTH), ftee T3 (FT3),
free T4 (FT4), thyroid-stimulating hormone (TSH), and
anti-acetylcholine receptor antibody (anti-AchR Ab)
were also within normal range. No adverse events oc-
curred during the course of this immunotherapy.
After six courses of this immunotherapy, an FDG-PET
scan showed decreased FDG uptake in each recurrent
lesion (Fig. 2). Serum carcinoembryonic antigen (CEA)
levels were also decreased (Fig. 3).
Discussion
In patients with recurrent or advanced NSCLC, who
have relapsed after previous platinum-based chemother-
apy or EGFR-TKI, docetaxel monotherapy is considered
to be the current standard treatment regimen [5, 7]. In a
phase III study involving docetaxel in patients with
NSCLC previously treated with platinum-based chemo-
therapy, the time to progression and median survival
time (MST) after docetaxel monotherapy has been re-
ported to be 10.6 weeks and 7.0 months, respectively [6].
Recent prospective studies including CheckMate 017
[13] and CheckMate 057 [14] showed that nivolumab
was superior to docetaxel for squamous cell carcinoma
Fig. 1 Hematoxylin and eosin (H&E) staining (×100) (a) and immunohistochemical staining for PD-L1 (b) of surgically resected NSCLC tissue. H&E
staining showed invasive adenocarcinoma papillary predominant type and immunohistochemical staining showed negative for PD-L1
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and non-squamous cell carcinoma previously treated
with platinum-based agents. Based on these studies, the
current second-line chemotherapy in patients failing
platinum-based chemotherapy is considered to be nivolu-
mab. These studies suggested that a radiological response
had been detected approximately 8 weeks (4th course)
after initial administration of nivolumab.
The combination of FDG-PET and computed tomog-
raphy (CT) is an effective tool for assessing treatment
response and for surveillance for disease recurrence in
cases treated with chemotherapy or radiation. Many
investigators have reported the utility of FDG-PET or
FDG-PET/CT in evaluating therapeutic response
prospectively or retrospectively [17–20]. Complete dis-
appearance of abnormal FDG accumulation is an indica-
tor of a low probability of local recurrence and better
prognosis after treatment such as surgery, radiation, and
chemotherapy. Immunotherapy presents a potential
problem because the inflammatory changes caused by
the recruitment of neutrophils, lymphocytes, and macro-
phages [15] may lower the specificity because these cells
take up FDG. More specifically, immune checkpoint in-
hibitors activate T cells, which infiltrate tumor tissue.
Uptake by the T cells might affect the evaluation of im-
munotherapy. To date, there is only one report except
our case, which showed the usefulness of FDG-PET/CT
Fig. 2 FDG uptake before (a) and after (b) immunotherapy. Maximum standardized uptake value (SUVmax) of supraclavicular lymph node and
disseminated lesions before and after immunotherapy decreased from 9.8 to no accumulation and 5.9 to 3.4, respectively. Each SUVmax was
decreased after six courses of nivolumab treatment
Fig. 3 Clinical course of serum carcinoembryonic antigen (CEA) levels during treatment. Serum CEA level decreased from 1335.0 to 108.4 ng/mL
after six courses of nivolumab treatment
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to evaluate the efficacy of nivolumab in a patient with
indolent Hodgkin lymphoma [21]. Although we usually
evaluate the anatomic tumor response with RECIST [16]
or immune-related Response Criteria (irRC) [22] after
cancer treatment, Wall et al. [23] proposed PET Response
Criteria in Solid Tumors version 1.0 (PERCIST) to assess
the treatment response instead of RECIST. PERCIST eval-
uates the metabolic tumor response using the change of
SUV ratio in the region of interest between the tumor and
liver. The evaluation criteria of PERCIST would be more
helpful to evaluate the treatment effects in the cases with
FDG-PET.
The optimal follow-up schedule of FDG-PET scan dur-
ing immunotherapy is unclear. In fact, little is known
about the role of FDG-PET and CT scan as appropriate
radiological modalities. Some exploratory clinical studies
(UMIN000020707 and UMIN000020814) have been
conducted and ongoing in Japan to evaluate FDG-PET
in nivolumab therapy. In our case, FDG-PET was consid-
ered to be a useful tool for the evaluation during immuno-
therapy. However, it is uncertain what the optimal timing
of FDG-PET scanning will yield the highest specificity and
sensitivity. More research in this area is needed.
An urgent issue to be resolved is to explore more spe-
cific biomarker of this treatment because the correlation
between PD-L1 expression by the tumor tissue and
treatment effect with nivolumab has not been quantified.
However, immunotherapy shows promise to improve the
prognosis of patients with unresectable or recurrent
NSCLC.
Conclusions
We have found decreased FDG uptake by tumor after
six courses of nivolumab treatment, suggesting the po-
tential value of FDG-PET in monitoring the response to
this immunotherapy. T cell activation and infiltration
into tumor tissue did not affect the results of FDG-PET
in this case. We await detailed results of ongoing clinical
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